Validation of a conceptually new treatment for glioblastoma multiforme with an IP protected small molecule

Project Information

GlioVac

Grant agreement ID: 637047

DOI

10.3030/637047

Project closed

EC signature date 2 February 2015

Start date 1 March 2015

End date 31 August 2016

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost

€ 149 693,00

EU contribution

€ 149 693,00

Coordinated by

KAROLINSKA INSTITUTET
Sweden

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features

Author(s): Lars G. J. Hammarström, Robert K. Harmel, Mikael Granath, Rune Ringom, Ylva Gravenfors, Katarina Färnegårdh, Per H. Svensson, David Wennman, Göran Lundin, Ylva Roddis, Satish S. Kitambi, Alexandra Bernlind, Fredrik Lehmann, Patrik Ernfors
Published in: Journal of Medicinal Chemistry, Issue 59/18, 2016, Page(s) 8577-8592, ISSN 0022-2623
Publisher: American Chemical Society
DOI: 10.1021/acs.jmedchem.6b01009